Still the shiny object or real wins with measurable outcomes and returns on investment? That’s perhaps a key question on the minds of several stakeholders across sectors, including pharma, when it comes to assessing the trajectory of generative artificial intelligence (GenAI) in driving efficiencies and business value.
Recent headlines suggesting that over 25% of GenAI projects could be dumped after proof of concept (PoC) by the end...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?